MRK · Merck & Company Inc. Common Stock (new)

October 16, 2026

Merck Stock Rally Draws Attention to Valuation Concerns. Recent market commentary highlights a renewed confidence in Merck, with analysts debating whether the current rally has priced in too much optimism. While comparisons with peers like AbbVie and Bristol Myers Squibb focus on dividend yields and value, the primary discussion centers on the sustainability of Merck's recent price movement. The stock's high trailing P/E ratio of 112.6 provides context for these valuation concerns, suggesting that investors are closely monitoring if the current momentum can be sustained.